NEW YORK (GenomeWeb News) – Maven Biotechnologies is seeking a buyer for its label-free detection and imaging technology.

The technology called LFIRE is a method for detection and ellipsometry reflection and provides enhanced, high-content, label-free detection and imaging and high-capacity screening. Today, BioMed Transition Partners announced Maven Bio has retained its services to help find a buyer for the technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.